Downloads
Article: Clinical Trial Outsourcing: Why China?
By Mike Anello, Life Science Leader magazine
Recent trends show that an ever-increasing percentage of clinical trials are being performed offshore. As the pressure increases to reduce the cost of prescription drugs, pharmaceutical manufacturers search for ways to reduce costs in research and production. Outsourcing of clinical trials can provide many benefits to the enterprise interested in reducing preapproval expenditures. However, many factors such as national infrastructure, patient pool, quality of data, and clinical expertise must be weighed before selecting the appropriate venue for each particular trial.
Marc Hagan, CEO for Cordium Links, a provider of cardiac safety assessment and diagnostic services for biopharmaceutical companies and clinical research organizations (CROs), views the outsourcing of clinical trial work as a positive, cost-effective alternative for companies needing such services. Hagan says, "There are hot spots of activity for North American pharmaceutical companies to offshore their clinical research. These include places such as Latin America, Eastern Europe, and Russia." Countries like Argentina, Brazil, and Poland, once leaders in offshore clinical trials, still achieve modest double-digit growth rates. However, India and China stand poised to accept ever-increasing and important roles in the future of offshore clinical trials. Hagan agrees, adding that, "China's most recent three-year clinical trials growth rate is projected to be 43%, India's is 46%, and of the other countries, none are even close to those numbers. In fact, the closest is Russia at 23%."
Used with permission from Life Science Leader magazine.
The content you requested is only available to registered users of Pharmaceutical Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
